Polyvinyl Alcohol Patents (Class 514/772.2)
-
Patent number: 7485670Abstract: In preferred embodiments, the present invention provides methods of controllably making a vinyl polymer hydrogel having desired physical properties without chemical cross links or radiation. The gelation process is modulated by controlling, for example, the temperature of a resultant vinyl polymer mixture having a gellant or using active ingredients provided in an inactive gellant complex.Type: GrantFiled: February 4, 2004Date of Patent: February 3, 2009Assignee: Cambridge Polymer Group, Inc.Inventors: Jeffrey W. Ruberti, Gavin J. C. Braithwaite
-
Patent number: 7465440Abstract: A process for preparing graft copolymers of polyvinyl esters by polymerization of a) at least one vinyl ester of aliphatic C1-C24-carboxylic acids in the presence of b) polyethers which are solid at room temperature and have the general formula I, c) and, where appropriate, at least one other monomer using a free-radical organic initiator system, wherein liquid polyalkylene glycol is used as solvent for the free-radical initiator system (feed).Type: GrantFiled: January 24, 2001Date of Patent: December 16, 2008Assignee: BASF AktiengesellschaftInventors: Maximilian Angel, Michael Gotsche, Karl Kolter
-
Publication number: 20080305150Abstract: A composition comprising a high molecular weight, water soluble polymer having a cloud point from about 20 to about 90° C. and a gelling polymer is provided. The composition may be used as a component of a pharmaceutical dosage form, such as the shell of a dosage form, or as an edible matrix, i.e., a pharmaceutical dosage form per se.Type: ApplicationFiled: March 17, 2008Publication date: December 11, 2008Inventors: Jen Chi Chen, Frank J. Bunick, Harry S. Sowden
-
Patent number: 7429619Abstract: Water soluble, gelatin-free dip coatings for substrates comprising an acrylic film former; a paraben plasticizer; and a secondary plasticizer such as polyvinylpyrrolidone, polyethylene glycol 300, polyethylene glycol 400 or mixtures thereof.Type: GrantFiled: August 2, 2002Date of Patent: September 30, 2008Assignee: McNeil Consumer HealthcareInventor: Satish Kamath
-
Patent number: 7423028Abstract: Injectable pharmaceutical compositions are described comprising sodium diclofenac, a ?-cyclodextrin and a polysorbate, suitable for subcutaneous and intramuscular administration.Type: GrantFiled: June 21, 2005Date of Patent: September 9, 2008Assignee: Ibsa Institut Biochemique S.A.Inventors: Giorgio Zoppetti, Nadia Puppini, Marco Pizzutti
-
Patent number: 7332230Abstract: A multilayer preparation in the form of films of hydrophilic polymers for rapid release of substances present in the film layers into liquid surroundings is characterized in that adjacent layers differ from one another in that in each case one layer is soluble in a nonaqueous solvent in which the respective adjacent layer is insoluble or only slightly soluble.Type: GrantFiled: November 3, 2000Date of Patent: February 19, 2008Assignee: LTS Lohmann Therapie-Systeme AGInventor: Markus Krumme
-
Patent number: 7323194Abstract: The present invention relates to a hydrophilic antimicrobial coating composition for an air conditioner evaporator of a vehicle with improved durability. In one embodiment of the present invention, the antimicrobial composition comprises a hydrophilic organic polymer with molecular weight in the range of about 4,000 to 8,000, a smoothing agent, an antimicrobial agent, and deionized water. In particular, the degree of polymerization between the hydrophilic functional group and a crosslinking group of the hydrophilic organic polymer is greatly improved. The antimicrobial composition is prepared with particles with a diameter of a few nanometers, which increases the number of particles per unit area and reduces the decomposition rate of the coated layer.Type: GrantFiled: July 13, 2005Date of Patent: January 29, 2008Assignee: Hyundai Motor CompanyInventor: Byeong Moo Jang
-
Patent number: 7229647Abstract: A method of making a composition having the property of being able to store chlorine dioxide includes mixing an aqueous chlorine dioxide solution with a superabsorbent, water-soluble polymer that is substantially unreactive with chlorine dioxide and permitting a mixture formed thereby to form one of a gel and a solid composition. A method of delivering chlorine dioxide includes providing a gel or solid composition as described and degelling the gel or dissolving the solid composition to dispense the chlorine dioxide therefrom. A method of disinfecting a target such as water, wastewater, or a surface comprises delivering chlorine dioxide as above and permitting the polymer to precipitate out of the mixture. Aqueous chlorine dioxide is then recovered and applied to the target.Type: GrantFiled: October 9, 2003Date of Patent: June 12, 2007Inventors: Sunggyu Lee, Patricia Roberts
-
Patent number: 7115586Abstract: The invention provides a number of methods for enhancing the aqueous solubility of an active ingredient which is insoluble or sparingly soluble in water. In one preferred embodiment, solubilization of the active ingredient is enhanced by combining it with ?-cyclodextrin in an aqueous complexation medium comprising ?-cyclodextrin and a negatively- or positively-charged compound which forms an inclusion or non-inclusion complex with ?-cyclodextrin and its inclusion complexes.Type: GrantFiled: October 18, 2002Date of Patent: October 3, 2006Assignee: Decode Genetics EHF.Inventor: Thorsteinn Loftsson
-
Patent number: 7109255Abstract: Crosslinked compositions formed from water-insoluble copolymers are disclosed. These compositions are copolymers having a bioresorbable region, a hydrophilic region and at least two cross-linkable functional groups per polymer chain. Crosslinking of these polymers can be effected in solution in organic solvents or in solvent-free systems. If crosslinking occurs in a humid environment, a hydrogel will form. If crosslinking occurs in a non-humid environment, a xerogel will form which will form a hydrogel when exposed to a humid environment and the resulting crosslinked materials form hydrogels when exposed to humid environments. These hydrogels are useful as components in medical devices such as implantable prostheses. In addition, such hydrogels are useful as delivery vehicles for therapeutic agents and as scaffolding for tissue engineering applications.Type: GrantFiled: August 27, 2004Date of Patent: September 19, 2006Assignee: Scimed Life Systems, Inc.Inventors: Gary L. Loomis, D. Christian Lentz
-
Patent number: 7105180Abstract: The invention relates to a novel benzimidazole formulation and to a process for its production. The benzimidazole formulation comprises a layer comprising the benzimidazole compound together with an acidic reacting compound.Type: GrantFiled: December 6, 2000Date of Patent: September 12, 2006Assignee: Ratiopharm GmbHInventor: Benoit Schmitt
-
Patent number: 7101840Abstract: A method of forming a polymeric drug formulation in which a water-soluble drug is blended with a water-insoluble tissue-compatible polymer that is miscible in the solid phase with the drug, and with a poly(alkylene oxide), in a solvent system capable of forming a homogeneous solution of the drug, the tissue-compatible polymer and the poly(alkylene oxide), after which the solution is added to a non-solvent for the drug, the tissue-compatible polymer and the poly(alkylene oxide), so that a microdomain-separated solid co-precipitate of the drug, the tissue-compatible polymer and the poly(alkylene oxide) is formed, wherein the poly(alkylene oxide) is blended in an amount effective to form phase-separated microdomains in said co-precipitate.Type: GrantFiled: June 21, 2002Date of Patent: September 5, 2006Assignee: Rutgers, The State UniversityInventors: Stephen Brocchini, Stephen R. Hanson, Joachim B. Kohn
-
Patent number: 7084132Abstract: A stable form of artemisinin wherein an artelinic acid or artesunic acid is complexed with cyclodextrin analogs, preferably, ?-cyclodextrin. The complexed cyclodextrin artemisinin formulation shields the peroxide portion of the artemisinin backbone from hydrolytic decomposition rendering it stable in solution. Artelinic acid and cyclodextrin are placed into contact with one another to yield a 2:1 molecular species. Artesunic acid and cyclodextrin yield a 1:1 molecular species. The complexed cyclodextrin artemisinin formulation is effective for the treatment of malaria and is stable in solution for long periods of time.Type: GrantFiled: April 25, 2005Date of Patent: August 1, 2006Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Mark G. Hartell, Apurba K. Bhattacharjee, Rickey P. Hicks, John E. VanHamont, Wilbur K. Milhous
-
Patent number: 7022740Abstract: There are provided lubricious ophthalmic solutions having a pH of between about 7.0 and about 8.0, consisting essentially of an aqueous solution of from about 0.5–4% by weight of a monographed polyol, borate calculated as the borate equivalent of 20–100% by weight of boric acid relative to said polyol, from about 0.1 to about 1.00% by weight of monographed polysorbate, a monographed preservative and a buffer. Suitably the polyol is polyvinyl alcohol In addition to polyvinyl alcohol (hereinafter PVA) the solution may include other monographed polymers as well as monographed pharmacologically active substances.Type: GrantFiled: April 29, 2004Date of Patent: April 4, 2006Inventor: Leonard Mackles
-
Patent number: 6951846Abstract: A stable form of artemisinin wherein an artelinic acid or artesunic acid is complexed with cyclodextrin analogs, preferably, ?-cyclodextrin. The complexed cyclodextrin artemisinin formulation shields the peroxide portion of the artemisinin backbone from hydrolytic decomposition rendering it stable in solution. Artelinic acid and cyclodextrin are placed into contact with one another to yield a 2:1 molecular species. Artesunic acid and cyclodextrin yield a 1:1 molecular species. The complexed cyclodextrin artemisinin formulation is effective for the treatment of malaria and is stable in solution for long periods of time.Type: GrantFiled: February 27, 2003Date of Patent: October 4, 2005Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Mark G. Hartell, Apurba K. Bhattacharjee, Rickey P. Hicks, John E. VanHamont, Wilbur K. Milhous
-
Patent number: 6946499Abstract: Crosslinked compositions formed from water-insoluble copolymers are disclosed. These compositions are copolymers having a bioresorbable region, a hydrophilic region and at least two cross-linkable functional groups per polymer chain. Crosslinking of these polymers can be effected in solution in organic solvents or in solvent-free systems. If crosslinking occurs in a humid environment, a hydrogel will form. If crosslinking occurs in a non-humid environment, a xerogel will form which will form a hydrogel when exposed to a humid environment and the resulting crosslinked materials form hydrogels when exposed to humid environments. These hydrogels are useful as components in medical devices such as implantable prostheses. In addition, such hydrogels are useful as delivery vehicles for therapeutic agents and as scaffolding for tissue engineering applications.Type: GrantFiled: October 10, 2003Date of Patent: September 20, 2005Assignee: SciMed Life Systems, Inc.Inventors: Gary L. Loomis, D. Christian Lentz
-
Patent number: 6899896Abstract: A controlled release dosage form for sertraline has a core comprising a sertraline-containing composition and a water-swellable composition wherein the water-swellable composition is in a separate region within the core. A coating around the core is water-permeable, water-insoluble, and has at least one delivery port therethrough. In one embodiment, the dosage form releases sertraline to the use environment at an average rate of 6 to 10 wt % per hour from the second to the twenth hour after introduction to a use environment and less than about 25 wt % for the first two hours and at least 70 wt % by the twelfth hour, where the percentages correspond to the mass of drug released from the tablet divided by the total mass of drug originally present in the tablet.Type: GrantFiled: December 20, 2000Date of Patent: May 31, 2005Assignee: Pfizer IncInventors: William J. Curatolo, Kenneth C. Waterman, Avinash G. Thombre, Michael B. Fergione, Michael C. Roy, Leah A. Appel, Danni Supplee, Dwayne T. Friesen, Mark B. Chidlaw, Ronald A. Beyerinck
-
Patent number: 6858216Abstract: There is provided cosmetic agents containing 2-furanone derivatives for the treatment of skin and hair.Type: GrantFiled: November 6, 2002Date of Patent: February 22, 2005Assignee: Henkel Kommanditgesellschaft auf AktienInventors: Erik Schulze zur Wiesche, Detlef Hollenberg, Britta Bossmann
-
Patent number: 6828334Abstract: The present invention relates to pharmaceutical compositions containing fenofibrate in the form of an inclusion complex with cyclodextrin, having high dissolution profile and in vivo enhanced bioavailability as compared with plain micronized fenofibrate compositions. An inclusion complex has a molar ratio of fenofibrate (preferably in micronized form) to cyclodextrin of from about 1:0.5 to about 1:4, preferably from about 1:1 to about 1:2. The immediate release fenofibrate composition is preferably in the form of a tablet or in the form of granules inside a capsule.Type: GrantFiled: January 7, 2003Date of Patent: December 7, 2004Assignee: USV LimitedInventors: Suresh Kumar Gidwani, Purushottam Sharshikant Singnurkar
-
Patent number: 6818247Abstract: A composition comprising an ethylene vinyl alcohol copolymer and a dimethyl acetamide solvent is provided for forming a coating on prostheses such as stents. The composition can include an active agent or therapeutic substance. Methods are also provided for coating the stents.Type: GrantFiled: April 27, 2001Date of Patent: November 16, 2004Assignee: Advanced Cardiovascular Systems, Inc.Inventors: Yung-Ming Chen, Syed F. A. Hossainy, Deborra Sanders Millare, Wouter E. Roorda, Ashok A. Shah
-
Patent number: 6800663Abstract: The present invention relates to crosslinked polymers, synthesized through ring-opening polymerization of ethylenically unsaturated epoxides, in combination with &agr;-hydroxy acids using a hydrophilic macroinitiator, such as poly(ethylene glycol), to form substituted copolymers having ethylenically unsaturated functionality randomly distributed along the polyester polymer backbone. That copolymer is subsequently crosslinked to form a hydrogel network. More particularly, the present invention relates to the synthesis of biodegradable poly(&agr;-hydroxy acid-co-glycidyl methacrylate)-block-poly(ethylene glycol)-block-poly(&agr;-hydroxy acid-co-glycidyl methacrylate) copolymers, which are subsequently crosslinked to form hydrogel networks. The invention also relates to the use of these hydrogel networks in various applications, in particular, for the controlled release of drugs and proteins.Type: GrantFiled: October 18, 2002Date of Patent: October 5, 2004Assignee: Alkermes Controlled Therapeutics Inc. II,Inventors: Firouz Asgarzadeh, Henry R. Costantino
-
Patent number: 6761903Abstract: The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a carrier, where the carrier is formed from a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the carrier forms a clear, aqueous dispersion of the triglyceride and surfactants.Type: GrantFiled: June 8, 2001Date of Patent: July 13, 2004Assignee: Lipocine, Inc.Inventors: Feng-Jing Chen, Mahesh V. Patel, David T. Fikstad
-
Patent number: 6749869Abstract: The mastitis control teat dip composition of the invention provides rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The compositions of the invention are made by combining an aqueous thickened liquid composition containing the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite. The materials can be combined, blended into a smooth viscous material and can be immediately contacted with the target animals. The compositions of the invention provide rapid initial kill, consistent long term kill and chemical and rheological stability.Type: GrantFiled: September 26, 1997Date of Patent: June 15, 2004Assignee: EcolabInventors: Francis L. Richter, Cathy M. Paquette, Richard K. Staub
-
Patent number: 6730327Abstract: A polymer blend is prepared by dissolving chitosan and a second polymer in an acidic aqueous solution to form an aqueous polymer blend, dehydrating said aqueous polymer blend, and recovering said polymer blend. The second polymer may be selected from the group consisting of polyether glycols including polyethylene glycols; cellulose esters including cellulose acetate; poloxamers; polysaccharides including dextran and guar; polyvinylpyrrolidones; polyvinyl alcohols; and mixtures or copolymers thereof. These polymer blends swell in an acidic environment and deswell in a more neutral or basic environment. This technology is valuable for the dispensing of biologically active material or drugs into a surrounding environment, especially the environment as is found in the gastrointestinal tract.Type: GrantFiled: December 20, 2002Date of Patent: May 4, 2004Assignee: MacroMed, Inc.Inventors: Gaylen M. Zentner, Jong-Seok Bark, Feng Liu
-
Patent number: 6703011Abstract: Described is a fragrance control release system which is an emulsifier-free, single phase, nonporous, continuous, permeable polymeric film having a substantially uniform thickness of from about 1 up to about 150 microns, having entrapped and dissolved therein molecules of at least one fragrance substance capable of evolving from said film into the environment proximate said film by means of molecular diffusion at a permeation rate of from about 1×10−7 up to about 0.1 mg-mm/cm2-min in a sustained and controlled release manner. Also described is a process for using the aforementioned system for imparting a fragrance into the environment above the unobstructed outer surface of the aforementioned polymer film which is coated on the surface of a solid or semi-solid support, e.g., a woven or non-woven fabric substrate; or a solid surface or human epidermis.Type: GrantFiled: June 27, 2001Date of Patent: March 9, 2004Assignee: International Flavors & Fragrances Inc.Inventors: Adi Shefer, Shmuel David Shefer, Michael John Robert White
-
Patent number: 6699510Abstract: The mastitis control teat dip composition having a visible indicator aspect of the invention provides a softening, soothing, smoothing, relaxing property, a rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The indicator aspect provides ease of visually detecting the material on the animal skin and can indicate efficacy of the material. The compositions of the invention are made by combining an aqueous liquid composition containing the visual indicator combined with the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite.Type: GrantFiled: August 19, 2002Date of Patent: March 2, 2004Assignee: Ecolab Inc.Inventors: David D. McSherry, Francis L. Richter
-
Patent number: 6676971Abstract: Embolic compositions comprising macromers having a backbone comprising a polymeric backbone comprising units with a 1,2-diol or 1,3-diol structure, such as polyvinyl alcohol, and pendant chains bearing crosslinkable groups and, optionally, other modifiers. When crosslinked, the macromers form hydrogels having many properties advantageous for use as embolic agents to block and fill lumens and spaces. The embolic compositions can be used as liquid embolic agents and crosslinked in situ or as preformed embolic articles, such as microspheres.Type: GrantFiled: March 13, 2001Date of Patent: January 13, 2004Assignee: BioCure, Inc.Inventors: Dennis W. Goupil, Hassan Chaouk, Troy Holland, Bruktawit T. Asfaw, Stephen D. Goodrich, Lucas Latini
-
Patent number: 6660827Abstract: Crosslinked compositions formed from water-insoluble copolymers are disclosed. These compositions are copolymers having a bioresorbable region, a hydrophilic region and at least two cross-linkable functional groups per polymer chain. Crosslinking of these polymers can be effected in solution in organic solvents or in solvent-free systems. If crosslinking occurs in a humid environment, a hydrogel will form. If crosslinking occurs in a non-humid environment, a xerogel will form which will form a hydrogel when exposed to a humid environment and the resulting crosslinked materials form hydrogels when exposed to humid environments. These hydrogels are useful as components in medical devices such as implantable prostheses. In addition, such hydrogels are useful as delivery vehicles for therapeutic agents and as scaffolding for tissue engineering applications.Type: GrantFiled: February 19, 2003Date of Patent: December 9, 2003Assignee: Scimed Life Systems, Inc.Inventors: Gary L. Loomis, D. Christian Lentz
-
Patent number: 6660382Abstract: The invention concerns a method for making coated granules with masked taste and instant release of the active principle which consists in: first, mixing the constituents of a powder comprising at least the active principle and a granular disintegrating agent; then, granulating the resulting powder, in the presence of a mixture of carriers comprising at least a binding agent capable of binding the particles together to obtain grains; coating the grains formed by spraying a suspension comprising at least a coating agent and a membrane disintegrating agent; finally drying the resulting coated granules.Type: GrantFiled: January 8, 2002Date of Patent: December 9, 2003Assignee: EthypharmInventors: Noureddine Nouri, Jean-Marc Zuccarelli, Charles Chauveau, Etienne Bruna
-
Patent number: 6652883Abstract: Compositions comprising macromers having a backbone comprising units having a 1,2-diol and/or 1,3-diol structure for tissue bulking and coating. Such polymers include poly(vinyl alcohol) (PVA) and hydrolyzed copolymers of vinyl acetate, for example, copolymers with vinyl chloride, N-vinylpyrrolidone, etc. The backbone polymer contains pendant chains bearing crosslinkable groups and, optionally, other modifiers. When crosslinked, the macromers form hydrogels having many properties advantageous for use as agents to bulk and coat tissues.Type: GrantFiled: March 13, 2001Date of Patent: November 25, 2003Assignee: BioCure, Inc.Inventors: Dennis W. Goupil, Hassan Chaouk, Troy Holland, Bruktawit T. Asfaw, Stephen D. Goodrich, Lucas Latini
-
Publication number: 20030149106Abstract: Water-in-oil emulsions, compositions, and methods that include a vinyl polymer that includes ethylene oxide-containing side chains and alkyl-Y-containing side chains, wherein Y is O or NR, wherein R is H or CH3, and wherein the alkyl group of the alkyl-Y-containing side chain has at least 4 carbon atoms on average in a cyclic, branched-, or straight-chain configuration and optionally including one or more heteroatoms.Type: ApplicationFiled: September 28, 2001Publication date: August 7, 2003Applicant: 3M Innovative Properties CompanyInventors: Deral T. Mosbey, Gilbert L. Eian, Matthew T. Scholz, Richard A. Mallo, Ling Lu
-
Patent number: 6602915Abstract: Polyazo compounds, which include low molecular weight drugs having a carboxylic acid group and an amine, thiol, alcohol or phenol group within their structure, formed into polymeric drug delivery systems are provided. Also provided are methods of producing polymeric drug delivery systems having these polyazo compounds as well as methods of administering low molecular weight drugs to a host via the polymeric drug delivery systems.Type: GrantFiled: July 27, 2001Date of Patent: August 5, 2003Assignee: Rutgers, The State University of New JerseyInventor: Kathryn E. Uhrich
-
Patent number: 6592859Abstract: A composition for injecting into tissues surrounding the urethra or ureter. It comprises a plurality of physiologically acceptable solid polymer particles dispersed in a physiologically acceptable biodissipatable liquid carrier. The polymer comprises a hydrophilic component and may also include a non-hydrophilic component. The polymer hydrates and swells to a predetermined volume as the liquid carrier dissipates. The composition is especially suitable in treating patients with urinary incontinence and patients with vesicoureteral reflux via injection into the tissues around the urethra or ureter.Type: GrantFiled: August 20, 1992Date of Patent: July 15, 2003Assignee: Ethicon, Inc.Inventor: Robert Steven Bley
-
Patent number: 6589511Abstract: The composition for forming solid particles of the present invention comprises a biodegradable polymer, a solvent, a polyhydric alcohol, a viscosity-increasing agent, and an active drug, wherein the composition is in the form of an emulsion comprising a continuous phase rich in the polyhydric alcohol and the viscosity-increasing agent and a dispersed phase of liquid particles rich in the biodegradable polymer and the solvent, the dispersed phase being present in said continuous phase. The above composition can allow the carrier comprising an active drug to reach all corners of narrow periodontal pockets, and the carrier comprising the active drug has high retention in the periodontal pockets, whereby making it possible to maintain the active drug for a long period of time at a high concentration.Type: GrantFiled: September 17, 1999Date of Patent: July 8, 2003Assignee: Sunstar, Inc.Inventor: Yasumitsu Shimizu
-
Patent number: 6562330Abstract: An insoluble polymer is deposited in a body cavity for instance to embolize a vein or pack an aneurysm, the polymer having pendant zwitterionic groups to improve biocompatibility. The insoluble polymer is preferably formed by an in situ gelling step in which a charged, preferably soluble, polymer having pendant zwitterionic groups is introduced in the form of a composition in which it is soluble and is gelled by being mixed with a counterionically charged soluble polymer (polyelectrolyte), to form a polyion complex. Preferably the or each soluble polymer is formed by polymerizing ethylenically unsatured monomers including a zwitterionic monomer, for instance 2-methacryloyloxyethyl-2′-trimethylammoniumethyl phosphate inner salt, an ionic monomer such as trimethylammonium alkyl(alk)acrylate or a sulphoalkyl(alk)acrylate and optionally a diluent monomer such as an alkyl(alk)acrylate.Type: GrantFiled: May 14, 2001Date of Patent: May 13, 2003Assignee: Biocompatibles LimitedInventors: Peter William Stratford, Jane Louise Court, Andrew Lennard Lewis
-
Patent number: 6562331Abstract: A mating disruption method for the control of insect pests comprises releasing a sex pheromone in a field wherein an adsorption of the sex pheromone to a soil in the field is decreased.Type: GrantFiled: August 10, 2000Date of Patent: May 13, 2003Assignee: Shin-Etsu Chemical Co., Ltd.Inventors: Tatsuya Ito, Takehiko Fukumoto, Kinya Ogawa, Fumiaki Mochizuki
-
Patent number: 6538039Abstract: The present invention relates to a process for administering an active principle to a patient transdermally, which comprises the formation of a film on the patient's skin, by applying to the skin a liquid solution which consists essentially of: a) a lipophilic active principle, b) from 2.5 to 25% by weight of a silicone-based adhesive polymer composition, c) from 0 to 25% by weight of an absorption promoter, and d) from 25 to 95% by weight of volatile solvents comprising volatile silicones.Type: GrantFiled: October 31, 1996Date of Patent: March 25, 2003Assignee: Laboratoire L. LafonInventor: Philippe Laurent
-
Patent number: 6537584Abstract: A polymer blend is prepared by dissolving chitosan and a second polymer in an acidic aqueous solution to form an aqueous polymer blend, dehydrating said aqueous polymer blend, and recovering said polymer blend. The second polymer may be selected from the group consisting of polyether glycols including polyethylene glycols; cellulose esters including cellulose acetate; poloxamers; polysaccharides including dextran and guar; polyvinylpyrrolidones; polyvinyl alcohols; and mixtures or copolymers thereof. These polymer blends swell in an acidic environment and deswell in a more neutral or basic environment. This technology is valuable for the dispensing of biologically active material or drugs into a surrounding environment, especially the environment as is found in the gastrointestinal tract.Type: GrantFiled: November 9, 2000Date of Patent: March 25, 2003Assignee: MacroMed, Inc.Inventors: Gaylen M. Zentner, Jong-Seok Bark, Feng Liu
-
Patent number: 6534560Abstract: Crosslinked compositions formed from water-insoluble copolymers are disclosed. These compositions are copolymers having a bioresorbable region, a hydrophilic region and at least two cross-linkable functional groups per polymer chain. Crosslinking of these polymers can be effected in solution in organic solvents or in solvent-free systems. If crosslinking occurs in a humid environment, a hydrogel will form. If crosslinking occurs in a non-humid environment, a xerogel will form which will form a hydrogel when exposed to a humid environment and the resulting crosslinked materials form hydrogels when exposed to humid environments. These hydrogels are useful as components in medical devices such as implantable prostheses. In addition, such hydrogels are useful as delivery vehicles for therapeutic agents and as scaffolding for tissue engineering applications.Type: GrantFiled: September 20, 2001Date of Patent: March 18, 2003Assignee: Scimed Life Systems, Inc.Inventors: Gary L. Loomis, D. Christian Lentz
-
Patent number: 6528086Abstract: This invention relates to an apparatus and method of drug delivery on a human body surface. The formulation comprises a drug, a conversion agent capable of converting the formulation from a less solid phase to a coherent, soft, solid phase, and a vehicle medium or carrier for the drug and conversion agent. The drug formulation is applied to this human body surface in its less than solid phase and is subsequently converted to a soft solid phase while the drug is being delivered through the human body surface. After delivery of the drug is complete, the soft solid formulation can be removed or peeled from the body surface as a coherent solid formulation. The drug formulation provides control over drug delivery rates and allows the formulation to be removed without leaving a messy, residual formulation on the body surface.Type: GrantFiled: September 28, 1999Date of Patent: March 4, 2003Assignee: Zars, Inc.Inventor: Jie Zhang
-
Patent number: 6503954Abstract: A biocompatible carrier and a composition for forming the carrier are disclosed. The carrier is made from an ethylene vinyl alcohol copolymer which can serve as a reservoir, allowing for the local delivery and sustained release of actinomycin D. The carrier can be formed from the ethylene vinyl alcohol, copolymer, a dimethylsulfoxide solvent, and actinomycin D. Alternatively, the carrier can be formed from an ethylene vinyl alcohol copolymer, a dimethylsulfoxide solvent, actinornycin D, and a wetting fluid. The carrier can serve as a coating for a prosthesis, for example a stent. The composition is applied to a surface of the prosthesis and essentially all of the dimethylsulfoxide solvent or dimethylsulfoxide solvent/wetting fluid is removed or allowed to evaporate to form the coating.Type: GrantFiled: July 21, 2000Date of Patent: January 7, 2003Assignee: Advanced Cardiovascular Systems, Inc.Inventors: Vinayak D. Bhat, Syed F. A. Hossainy, Daryush Mirzaee, Evgenia Mandrusov, Deborra Sanders-Millare, Judy A. Guruwaiya
-
Patent number: 6495163Abstract: A dry moisture barrier film coating composition for forming a moisture barrier film coating for pharmaceutical tablets and the like comprises polyvinyl alcohol, soya lecithin, and optionally a flow aid, a colorant, and/or a suspending agent. A liquid coating solution or dispersion for forming a moisture barrier film coating for pharmaceutical tablets and the like comprises polyvinyl alcohol, soya lecithin, water, and optionally a flow aid, a colorant, and/or a suspending agent. A method of coating pharmaceutical tablets and the like with a moisture barrier film coating comprises forming a liquid coating solution or dispersion for forming a moisture barrier film coating for pharmaceutical tablets and the like comprising polyvinyl alcohol, soya lecithin, water, and optionally a flow aid, a colorant, and/or a suspending agent, applying the coating solution or dispersion onto the tablets to form a film coating on the tablets, and drying the film coating on the tablets.Type: GrantFiled: September 23, 1998Date of Patent: December 17, 2002Assignee: BPSI Holdings, Inc.Inventor: Martin Philip Jordan
-
Patent number: 6462093Abstract: A process for producing a solid dispersion of a sparingly water-soluble medical substance which comprises subjecting the sparingly water-soluble medical substance, an amorphous state-inducing agent and an amorphous state-stabilizing agent to heat treatment or mechanochemical treatment; and a process for producing a solid dispersion of a sparingly water-soluble medical substance which comprises high-frequency heating the sparingly water-soluble medical substance and an amorphous state-stabilizing agent. These processes make it possible to make sparingly water-soluble medical substance amorphous at a temperature lower than those employed in the conventional methods. The solid dispersions of the armorphous sparingly water-soluble medical substances thus obtained have an improved mucosal or rectal absorption rate, which makes it possible to elevate their bioavailability.Type: GrantFiled: February 6, 1998Date of Patent: October 8, 2002Assignee: Nissan Chemical Industries, Ltd.Inventors: Misao Miyamoto, Toshihisa Oda
-
Patent number: 6451348Abstract: A method of manufacturing a porous matrix-type drug delivery system is provided. It comprises the steps of: dispersing, stirring, and emulsifying an aqueous solution of a drug in an organic solvent having a polymer compound and a surface active agent solved therein; thereafter forming it into a desirable matrix shape; lyophilizing or drying it at a low temperature or room temperature until the matrix surface is hardened; and drying it again in order to remove the water and the organic solvent.Type: GrantFiled: January 3, 2000Date of Patent: September 17, 2002Assignee: Korea Institute of Science and TechnologyInventors: Seo Young Jeong, Kuiwon Choi, Ick-Chan Kwon, Yong-Hee Kim, Jae Bong Choi, Kyu Back Lee
-
Patent number: 6436440Abstract: The use of copolymers comprising a) 50 to 99% by weight of at least one N-vinyllactam or N-vinylamine selected from the group consisting of N-vinylpyrrolidone, N-vinylpiperidone, N-vinylcaprolactam, N-vinylimidazole and methylated N-vinylimidazole or N-vinylformamide and b) 1 to 50% by weight of at least one monomer selected from the group of b1) C14-C30-alkyl esters of monoethylenically unsaturated C3-C8-carboxylic acids; b2) N—C8-C30-alkyl-substituted amides of monoethylenically unsaturated C3-C8-carboxylic acids; b3) N,N—C8-C30-dialkyl-substituted amides of monoethylenically unsaturated C3-C8-carboxylic acids; b4) vinyl esters of aliphatic C8-C30-carboxylic acids; b5) C8-C30-alkyl vinyl ethers as matrix for producing solid pharmaceutical and cosmetic presentations.Type: GrantFiled: April 1, 1999Date of Patent: August 20, 2002Assignee: BASF AktiengesellschaftInventors: Helmut Meffert, Folker Ruchatz
-
Patent number: 6436444Abstract: The mastitis control teat dip composition of the invention provides rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The compositions of the invention are made by combining an aqueous thickened liquid composition containing the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite. The materials can be combined, blended into a smooth viscous material and can be immediately contacted with the target animals. The .compositions of the invention provide rapid initial kill, consistent long term kill and chemical and rheological stability.Type: GrantFiled: September 26, 1997Date of Patent: August 20, 2002Assignee: Ecolab Inc.Inventors: Francis L. Richter, Cathy M. Paquette, Richard K. Staub
-
Patent number: 6432426Abstract: Non-staining topical iodine disinfecting compositions having the ability to inactivate pathogens associated with skin infections or diseases. based upon the presence of molecular iodine in a concentration above at least 15 ppm. Any other iodine species selected from the group consisting of complexed iodine and triiodide may be present with the total of such other iodine species limited to a concentration of less than about 700 ppm so that any visible stain resulting from the application of this composition on the skin will dissipate without leaving any visible skin coloration.Type: GrantFiled: December 12, 2000Date of Patent: August 13, 2002Assignee: Symbollon CorporationInventor: Jack Kessler
-
Patent number: 6423307Abstract: Mucoadhesive antimicrobial complexes of polycarbophil, i.e. a cross-linked polyacrylic acid with bioadhesive properties, and an imidazole or triazole derivative with antifungal or antiprotozoal activity, in its basic form, for use in the topical treatment of mucosal affections. The complexes are obtainable by dissolving each of the two starting products in a common solvent, then joining together the two solutions in relative amounts such as to contain the same number of equivalents of the two starting products, evaporating the solvent and then drying and, if required, pulverizing and sieving the product so obtained. Particularly preferred are formulations in gel in propylene glycol comprising an econazole-polycarbophil or omoconazole-polycarbophil complex, with an excess of polycarbophil, together with pharmaceutically acceptable carrier and excipient substances, for use as sustained release antifungals for vaginal administration.Type: GrantFiled: February 2, 1999Date of Patent: July 23, 2002Assignee: Farmigea S.p.A.Inventors: Marco Fabrizio Saettone, Luana Panichi, Boris Giannaccini, Enrico Boldrini, Pietro Bianchini
-
Patent number: 6413537Abstract: The present invention provides a novel formulation of nystatin for parenteral administration to treat systemic fungal infections. The formulation avoids the toxicity and solubility problems of prior art nystatin formulations.Type: GrantFiled: March 10, 2000Date of Patent: July 2, 2002Assignee: Wisconsin Alumni Research FoundationInventors: Glen S. Kwon, Bong K. Yoo
-
Patent number: 6395311Abstract: The present invention provides a novel vehicle for the delivery of biologically active agents. The vehicle, Maxcell™, is formulated from a novel combination of natural plant extracts and is comprised of Aloe vera polysaccharide fraction Immuno-10, cAMP, piperine, calcium phosphate and glycyrrhizinic acid.Type: GrantFiled: April 29, 1999Date of Patent: May 28, 2002Assignee: Univera Pharmaceuticals, Inc.Inventor: Qi Jia